CUSIP: 46333XAH1
What is CUSIP 46333XAH1?
CUSIP 46333XAH1 identifies 46333XAH1 - IRONWOOD PHARMACEUTICALS INC - NOTE 1.500% 6/1 in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Open recent reporting periods for CUSIP 46333XAH1:
As of 31 Dec 2025, 12 institutional investors reported holding $183,507,000 in principal (par value) of IRONWOOD PHARMACEUTICALS INC - NOTE 1.500% 6/1.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $183,507,000 | $177,678,590 | +$17,140,925 | 94.72% | 12 |
| 2025 Q3 | $170,823,077 | $177,255,350 | -$449,580 | 89.5% | 10 |
| 2025 Q2 | $167,434,077 | $168,923,031 | -$617,713 | 84.82% | 11 |
| 2025 Q1 | $165,440,927 | $177,805,855 | -$118,626 | 88.89% | 13 |
| 2024 Q4 | $162,485,927 | $181,412,896 | -$5,361,158 | 91.88% | 15 |
| 2024 Q3 | $174,660,250 | $155,061,380 | -$26,714,854 | 88.54% | 19 |
| 2024 Q2 | $199,579,000 | $188,232,680 | -$1,536,486 | 93.95% | 19 |
| 2024 Q1 | $197,210,000 | $200,950,767 | -$4,539,819 | 101.32% | 26 |
| 2023 Q4 | $197,783,681 | $214,752,759 | -$57,796,947 | 108.35% | 23 |
| 2023 Q3 | $253,984,309 | $234,677,877 | +$47,095,659 | 97.69% | 21 |
| 2023 Q2 | $195,096,314 | $199,278,621 | -$3,822,597 | 102.09% | 17 |
| 2023 Q1 | $199,068,000 | $199,949,244 | +$3,671,564 | 100.21% | 23 |
| 2022 Q4 | $193,506,792 | $212,083,816 | +$3,261,653 | 109.47% | 26 |
| 2022 Q3 | $172,661,287 | $175,938,133 | -$19,057,125 | 101.75% | 24 |
| 2022 Q2 | $191,310,000 | $206,431,392 | -$3,075,326 | 108.0% | 21 |
| 2022 Q1 | $193,608,500 | $227,878,494 | -$1,405,092 | 117.86% | 19 |
| 2021 Q4 | $195,546,000 | $222,198,820 | -$9,175,256 | 113.74% | 19 |
| 2021 Q3 | $198,153,834 | $243,379,250 | +$25,811,035 | 120.74% | 19 |
| 2021 Q2 | $176,649,934 | $211,202,719 | +$8,625,093 | 119.71% | 18 |
| 2021 Q1 | $169,573,934 | $191,711,949 | -$4,712,158 | 113.2% | 17 |
| 2020 Q4 | $173,803,000 | $196,230,527 | +$1,158,829 | 112.6% | 17 |
| 2020 Q3 | $173,624,321 | $169,841,000 | +$169,841,000 | 97.63% | 18 |